Energy for Lymphocytes

Hôpital Cochin144 enrolled

Overview

CERTIM is a cohort created in July 2015 to set up a multidisciplinary follow-up of cancer patients treated with immune checkpoint inhibitors. From the CERTIM cohort, we conducted a longitudinal, prospective, observational study (ELY) in two tertiary university centers (Cochin hospital and European Georges Pompidou Hospital), which included patients between August 2016 and October 2019 and ended follow-up in April 2020. Patients were treated with nivolumab, at a dose of 3 mg/kg every 2 weeks, or pembrolizumab, at a dose of 2mg/kg every 3 weeks. The investigators report findings from an evaluation of rest energy expenditure (REE) assessed using indirect calorimetry in the outpatient setting before treatment with checkpoints inhibitors.

Study Type

OBSERVATIONAL

Enrollment

144

Conditions

Non-small Cell Lung Cancer Progression, Disease

Interventions

Resting Energy Expenditure measurementOTHER

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years or older * Stage IV histologically proven Non Small Cell Lung Cancer (NSCLC) * Monotherapy with nivolumab or pembrolizumab. * Patients were required to have measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Exclusion Criteria: * Active malignancy other than NSCLC, * ALK or EGFR mutated NSCLC * Anticancer therapy or surgery within the past 2 weeks or inability to breathe under the calorimetry.

Outcomes

Primary Outcomes

6-month Progression-free survival

Calculated as the percentage of participants alive and without disease progression, as assessed by the Investigator using RECIST v1.1

Time frame: 6 months after start of treatment